Table IX.
Association between the expression of LINC01071 and clinicopathological characteristics of gastric cancer patients.
| Variable | Cases, n (%) | 2−ΔΔCq (mean ± standard deviation) Expression of LINC01071 | P-value |
|---|---|---|---|
| Gender | 0.988 | ||
| Male | 59 (72) | −12.848±37.204 | |
| Female | 23 (28) | −12.984±28.666 | |
| Age, years | 0.039a | ||
| ≤50 | 30 (37) | −12.208±21.206 | |
| >50 | 52 (63) | −3.312±13.601 | |
| Tumor size, cm | 0.679 | ||
| ≤5 | 43 (52) | −9.411±19.770 | |
| >5 | 39 (48) | −7.330±21.682 | |
| Degree of differentiation | 0.613 | ||
| Well/moderately | 28 (34) | −11.744±22.416 | |
| Poorly | 54 (66) | −8.719±25.297 | |
| TNM stage | 0.557 | ||
| I/II | 44 (54) | −9.716±19.924 | |
| III/IV | 38 (46) | −6.733±21.545 | |
| Lymph node status | 0.908 | ||
| No metastasis | 36 (44) | −9.720±20.630 | |
| Metastasis | 46 (56) | −10.392±27.488 |
a
Statistically significant (P<0.05). LINC01071, tumor suppressor candidate 8; TNM, tumor-node-metastasis.